RUBICON RESEARCH LIMITED vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of RUBICON RESEARCH LIMITED (RUBICON) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads RUBICON vs TORNTPHARM on 9 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has reduced debt.", "Company has delivered good profit growth of 52.0% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%"]
- − ["Stock is trading at 18.3 times its book value", "Working capital days have increased from 68.8 days to 104 days"]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 19.8 times its book value", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.